Immunocore and Medimmune team up to develop cancer therapies

21st January 2014

Immunocore has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.

Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.

Immunocore Ltd is a privately owned biotechnology company developing a technology that generates novel drugs for the treatment of cancer and viral infection.

Immunocore traces its roots to Avidex Ltd, founded in 1999 as a spin-out from Oxford University Innovation Ltd at the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.

Read more here.

Press release sign up